

BIOLIDICS LIMITED
(Company Registration No.: 200913076M)
(Incorporated in the Republic of Singapore)

**PROPOSED ISSUANCE OF UP TO 2,723,500 NEW ORDINARY SHARES IN THE ISSUED AND
PAID-UP SHARE CAPITAL OF BIOLIDICS LIMITED (THE "PROPOSED ISSUANCE")**

– ALLOTMENT AND ISSUANCE

The board of directors (the "**Board**") of Biolidics Limited (the "**Company**") refers to the Company's announcements dated 18 August 2020 and 30 August 2020 in relation to the Proposed Issuance ("**Announcements**"). Unless otherwise defined, capitalised terms used herein shall bear the same meanings ascribed to them in the Announcements.

Further to the Announcements, the Board wishes to announce that the Company had, on 31 August 2020, allotted and issued 1,168,000 New Shares to the Relevant Persons pursuant to the vesting of the New Shares.

The 1,168,000 New Shares shall rank *pari passu* in all respects with the existing issued ordinary shares of the Company. Following the allotment and issuance of the 1,168,000 New Shares, the total number of ordinary shares of the Company has increased from 262,879,000 ordinary shares to 264,047,000 ordinary shares.

The 1,168,000 New Shares are expected to be listed and quoted on Catalist on or about 2 September 2020.

BY ORDER OF THE BOARD

Leong Yow Seng
Lead Independent Director
31 August 2020

*This announcement has been prepared by the Company and has been reviewed by United Overseas Bank Limited (the "**Sponsor**") for compliance with Rules 226(2)(b) and 753(2) of the SGX-ST Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Lim Hoon Khat, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*